I am a PhD student in Dr. Robert Schneider’s lab, working on breast cancer at NYU School of Medicine. My goal is to elucidate the molecular basis for ER+ tamoxifen resistance and contribute to the discovery of new therapeutic targets that will be used for clinical intervention to benefit patients. I also serve as President at the NYU Biotech Association. My vision is to bridge the gap and forge collaborations among academia, healthcare industry and physicians. I am very interested in providing our members with opportunities to learn about areas of drug development, business, venture capital firms and life sciences entrepreneurship.
I am a PhD student in the Carlton lab where I am using computational models to analyze the neglected malaria parasite P. vivax. At the NYU Biotech association I am in charge of communications and outreach which means my main task is getting the word out there about our events but also interfacing with various other organizations like GRO Biotech. I want to motivate graduate students, postdocs and others to learn about the biopharma and biotech industries and get in touch with the great companies in the New York area.
I am a PhD student being co-advised by Dr. Daniel Turnbull and Dr. Fernando Boada studying early detection and treatment monitoring techniques for brain cancers using multi-modality imaging strategies. I am very interested in pursuing (and helping others pursue) “alternative” career paths after their graduate studies.
I am PhD student in Dr. Markus Schober's lab working on how tumor initiating cells maintain their ability to generate tumors. I believe that the research discovery to market route is the most effective way to bring about a positive change for people on a global scale. I am very interested in the process of bringing the discoveries made at the bench to a wider audience. This includes raising awareness in the general New York scientific community - students, postdocs, and faculty - about opportunities in biotech and also helping to develop the tools that are needed to branch into that area.
am a recently graduated PhD eager to blaze paths at the intersection of engineering, science, and communication. While my educational experiences in bioengineering, cardiac electrophysiology, prototyping, and consulting have been diverse and somewhat disparate, what ultimately motivates me is to better understand how the world works and to constantly push boundaries and learn! My specific goals in the biotech club are to help expose scientists to the variety of entrepreneurial opportunities in the greater NYC community and to empower women to excel in traditionally masculine environments.
I’m a PhD candidate in Cell and Molecular biology, investigating how commensal biofilm affect host’s aging, stress-resistance and innate immune response utilizing simple model organism, C. elegans. In parallel, I’m actively pursuing self-education in financial markets and financial modeling to gain in-depth understanding of financial operation and development in biotech sector. I see the future of NYU Biotech Club as key element in helping scientist to follow their passion for technology implementation.
I am a postdoctoral fellow in the lab of Dr. Mamta Tahiliani’s, working on genomic instability and epigenetics. My interest is to share with graduate students and other postdocs what PhDs have to offer to industry and how scientists can evolve outside of academia.
I am a Ph.D. candidate in the laboratory of Dr. Susan Schwab. I am studying the role of chemokine receptor signaling in T cell acute lymphoblastic leukemia to aid in the development of new therapeutic targets and clinical prognostic markers for the leukemia. Prior to joining NYU, I worked at a boutique, healthcare agency to develop market insights, corporate strategy and media relations for clients ranging from small biotech companies to large consumer good corporations. I hope to bring the insights gained from my industry experience to the NYUBA and continue to explore collaborative relationships between academia and biotech.
I’m an international PhD candidate working on Blood Stem Cell emergence. I’m very interested in following and contributing to the ever-growing Healthcare environment in NY and my personal goal is to build bridges between the NY based Graduate Biotech clubs to create an easy access, stable collaboration platform that would connect the student and postdoc talent to Biotechnology companies and Big Pharma.
Formerly a PhD candidate at NYU co-advised by Dr. Martin Blaser and Dr. Rich Bonneau. My main area of research is computational biology and microbiology. I develop statistical tools to make meaningful inferences in biological models of diseases that are influenced by microbial dysbiosis.
I am a Ph.D candidate at the NYU Perlmutter Cancer Center in the lab of Ramanuj Dasgupta. My research focuses on understanding how beta-catenin, a protein which is commonly misregulated in a number of cancer types, regulates the proliferation and survival of cancer and cancer stem cells. In my time at NYU, I have become increasingly interested in the intersection of biology and business, taking every opportunity to learn about topics such as funding startups, modeling drug revenue, and developing intellectual property. With the NYUBA, my goal is to help students and postdocs learn about and prepare for career opportunities outside of academia and connect them with both industry professionals and other students with similar interests.
Nicolette is the VP of Finance of the NYU Biotechnology Association, as well as a PhD candidate in the Molecular Biophysics Department of New York University Medical Center. She is conducting her thesis work in the lab of Dr. Da-Neng Wang, which involves crystallographic studies of a di- and tricarboxylate transporter that plays a role in regulating cellular metabolism. Through her work in lab, she has become increasingly interested in bridging the gap between academic and industrial research.
Dov Shamir is the co-president of the NYU Biotechnology Association and is a PhD candidate in the Neuroscience and Physiology program at NYU's School of Medicine. Dov is doing his thesis work in Dr. Einar Sigurdsson's Laboratory where he is studying the mechanisms of tau immunotherapies for Alzheimer's disease and other tauopathies. Since rebooting NYUBA in Spring 2012 Dov has focused on garnering an entrepreneur/innovative atmosphere within the university by integrating NYUBA initiatives with the NYU Entrepreneur Institute, NYC Tech Connect, and other city wide run organizations.
I am a Postdoctoral Fellow in Structural Biology at NYU. I investigate how kinase mutations cause cancer and aim to design potent cancer therapeutics using structure-based drug discovery. At NYUBA, I organize case studies that are aimed at educating students and postdocs about cutting-edge technologies, drug development, and product commercialization.
While learning about the intricacies of cytokine signaling in the context of the fibroblast growth factor (FGF) receptor tyrosine kinase (RTK) signaling axis during my PhD training in biophysics in the laboratory of Dr. Moosa Mohammadi, I had a unique opportunity to witness first-hand the development of a therapeutic we developed in collaboration with Pfizer. This partnership opened my perspectives to the career options PhD students are able to pursue with their finely-tuned analytical skills. My career goals currently lay at the intersection of scientific innovation and policy, where appropriate laws and regulations have the ability to facilitate funding, constructive evaluations, and even changing current guidelines to give previously rejected therapies and devices a chance to be repurposed and engineered to address the optimal people groups. Transparent collaboration between governing policies, pharmaceutical industries, and the all encompassing academic sector will prove vital for the continuation of developing therapies for ill-understood diseases.
